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Abstract
Background The racial/ethnic disparities in prostate can-
cer rates are well documented, with the highest incidence
and mortality rates observed among African-Americans
followed by non-Hispanic Whites, Hispanics, and Asian/
Pacific Islanders. Whether socioeconomic status (SES) can
account for these differences in risk has been investigated in
previous studies, but with conflicting results. Furthermore,
previous studies have focused primarily on the differences
between African-Americans and non-Hispanic Whites, and
little is known for Hispanics and Asian/Pacific Islanders.
Objective To further investigate the relationship between
SES and prostate cancer among African-Americans, non-
Hispanic Whites, Hispanics, and Asian/Pacific Islanders,
we conducted a large population-based cross-sectional
study of 98,484 incident prostate cancer cases and 8,997
prostate cancer deaths from California.
Methods Data were abstracted from the California Can-
cer Registry, a population-based surveillance, epidemiol-
ogy, and end results (SEER) registry. Each prostate cancer
case and death was assigned a multidimensional neigh-
borhood-SES index using the 2000 US Census data. SES
quintile-specific prostate cancer incidence and mortality
rates and rate ratios were estimated using SEER*Stat for
each race/ethnicity categorized into 10-year age groups.
Results For prostate cancer incidence, we observed higher
levels of SES to be significantly associated with increased
risk of disease [SES Q1 vs. Q5: relative risk (RR) = 1.28;
95% confidence interval (CI): 1.25–1.30]. Among younger
men (45–64 years), African-Americans had the highest
incidence rates followed by non-Hispanic Whites, Hispan-
ics, and Asian/Pacific Islanders for all SES levels. Yet,
among older men (75–84 years) Hispanics, following
African-Americans, displayed the second highest incidence
rates of prostate cancer. For prostate cancer deaths, higher
levels of SES were associated with lower mortality rates of
prostate cancer deaths (SES Q1 vs. Q5: RR = 0.88; 95%
CI: 0.92–0.94). African-Americans had a twofold to five-
fold increased risk of prostate cancer deaths in comparison
to non-Hispanic Whites across all levels of SES.
Conclusions Our findings suggest that SES alone cannot
account for the greater burden of prostate cancer among
African-American men. In addition, incidence and mor-
tality rates of prostate cancer display different age and
racial/ethnic patterns across gradients of SES.
Keywords Prostate cancer  Socioeconomic status 
Disparities  Incidence rates  Mortality rates
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Introduction
Prostate cancer is one of the leading causes of cancer
morbidity and mortality among men in the US with
186,320 new cases and 28,660 deaths estimated for 2008
[1]. Striking features of prostate cancer are the pronounced
racial/ethnic disparities in incidence and mortality rates.
African-Americans experience the highest burden of the
disease followed by non-Hispanic Whites, Hispanics, and
Asian/Pacific Islanders [2]. Reasons for these racial/ethnic
disparities remain poorly understood and are likely due to
the interplay of social, environmental, and genetic factors.
To better understand the interaction of these factors, the
relative contribution of each domain must be thoroughly
evaluated in relation to the disparity in rates of prostate
cancer.
Socioeconomic status (SES) is linked to several factors
that may collectively influence the burden of prostate can-
cer, including lifestyle and environmental risk factors as
well as access, quality, and utilization of screening and
health care services [3, 4]. In the years following adoption
of prostate specific antigen (PSA) screening for prostate
cancer, most studies reported associations between prostate
cancer and higher levels of SES [5–9]. However, incon-
sistent associations have been reported for different racial/
ethnic groups [10, 11]. Specifically, a large national US
study reported higher SES to be associated with increased
incidence of prostate cancer among non-Hispanic Whites,
but not among Hispanics or African-Americans [11];
whereas a study of men in the San Francisco Bay Area
observed a positive relationship with SES among Asian/
Pacific Islanders and Hispanics but not among non-Hispanic
Whites and African-Americans [10]. Less controversial are
associations of higher SES with lower mortality rates of
prostate cancer, which have been documented in multiple
studies [12–17].
It remains poorly understood whether SES may account
for the substantial racial/ethnic disparities in prostate can-
cer incidence and mortality among men in the US. Previous
studies have largely focused on explaining differences
between African-Americans and Whites without consider-
ation of other racial/ethnic groups. These studies generally
agree that SES does not entirely explain racial/ethnic dif-
ferences in prostate cancer incidence [5, 10, 18]. However,
findings have been mixed regarding the contribution of
SES to survival differences between racial/ethnic groups
[13–17, 19–21].
To further clarify the relationship between SES, race/
ethnicity, and prostate cancer incidence and mortality, we
studied a population-based series of prostate cancer
patients with large numbers of African-Americans, non-
Hispanic Whites, Hispanics, and Asian/Pacific Islanders for
whom small area-level SES information was available.
Materials and methods
Prostate cancer patients
We obtained from the California Cancer Registry (CCR),
comprising three of the National Cancer Institute’s sur-
veillance, epidemiology, end results (SEER) program reg-
istries, data regarding all 102,691 incident cases of invasive
prostate cancer (as mandated by state law) and 9,029
prostate cancer deaths reported for two time periods: 1
January 1998 to 31 December 2002 and 1 January 1999 to
31 December 2001 [‘‘International Classification of Dis-
eases for Oncology, Second Edition’’ (Percy, ICD-0, 1990)
site code C619]. These 5-year (incidence) and 3-year
(mortality) pericensal periods were chosen because the
appropriate census block group-level denominators needed
for neighborhood SES rate calculations were available for
the 2000 census. Information regarding patient age at can-
cer diagnosis, race/ethnicity, residential address at diagno-
sis, and tumor stage and grade was abstracted directly from
the medical record. Information regarding prostate cancer
deaths, including age, race/ethnicity, and residential address
at death, was obtained from death certificates. Race/eth-
nicity was classified as the following mutually exclusive
racial/ethnic groups: African-American, Asian/Pacific
Islander, Hispanic (of any race), non-Hispanic White, and
other/unknown. We defined nonaggressive disease as
tumors that were confined to the prostate and were either
well or moderately differentiated. Regional and distant
tumors or localized tumors that were poorly differentiated
or undifferentiated were classified as aggressive disease.
There were 9,712 tumors (9.9%) missing stage or grade
information; these tumors were included in all analyses
except for stratified analysis by aggressiveness of disease.
We restricted the present study to men aged 45 years
and older at diagnosis or death due to prostate cancer,
who were of known race/ethnicity. Men aged B45 years
(456 incident cases and 14 deaths) were excluded from
analysis due to small numbers as well as those with
unknown race/ethnicity (3,751 incident cases and 18
deaths), resulting in a final study population to 98,484
incident prostate cancer cases and 8,997 prostate cancer
deaths.
Socioeconomic status and population data
Individual-level SES characteristics (e.g., education,
income, and occupation) are not routinely collected by
most US cancer registries, including the CCR. However,
patient residential address at diagnosis is routinely geo-
coded by the CCR, and address at death was obtained from
California death certificate files. Residential addresses were
linked to neighborhood-level SES characteristics from the
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US Census Bureau. Census block group (an area containing
on average 1,500 residents) was the smallest geographic
census unit having information on both SES characteristics
and population counts in which we were able to estimate
incidence and mortality rates for the decennial census.
Patients for whom block group of residence was unknown
(incident cases: n = 5,139, 5.2%; deaths; n = 253; 2.8%)
were randomly allocated to block groups within the same
county. Patients with unknown block group did not differ
significantly (p B 0.05) from patients with known block
group on tumor characteristics of stage and grade.
We used a previously developed method [22] to assign a
single measure of SES to each California census block
group for the time periods in question. Cases diagnosed
from 1998–2002 and prostate cancer deaths from 1991–
2001 were linked to 2000 census data. Principal component
analysis was used to develop a single SES index from
seven census-based indicator variables of SES: mean years
of education; median household income; percent living
200% below poverty level; percent blue-collar workers;
percent older than 16 years in workforce without job;
median rent; and median house value [22]. Thus, this index
incorporates three critical domains of SES—education,
income, and occupation [23]. This index was used to assign
a standardized score to each block group, which was then
categorized into quintile levels. For each SES quintile,
‘‘Supplementary Table 1’’ shows the distribution of the
seven census-based indicator variables of SES and the
racial/ethnic distribution among the state of California.
Hispanics comprised the largest proportion of subjects for
SES quintiles 1 and 2, while non-Hispanic Whites were the
largest group for quintiles 3–5. For use as denominators in
rate calculation, we obtained population data from age-,
sex-, and race-specific population counts for census block
groups from the modified age, race, sex, and Hispanic
origin (‘‘MARS’’) files from the 2000 US census. Because
population estimates for census block groups were not
available for intercensal years, we multiplied the 2000
population counts by five and three, respectively, to esti-
mate the total population at risk for the 5-year period of
incidence and 3-year period of mortality.
Statistical analysis
Case counts and population estimates were stratified by 10-
year age groups, race/ethnicity, and neighborhood SES
quintile. Prostate cancer incidence and mortality rates were
calculated per 100,000 individuals. SES quintile-specific
incidence and mortality rate ratios (RR) and 95% confi-
dence intervals (CI) were estimated and when appropriate
age adjusted to the 2000 US standard population using
SEER*Stat, version 6.3.4.
Results
Socioeconomic status and prostate cancer incidence
For 98,484 incident cases of prostate cancer, the distribu-
tion of race/ethnicity, stage, grade, and neighborhood SES
quintile varied by 10-year age group (Table 1). Non-His-
panic Whites represented over 68% of all cases across all
age groups. African-Americans cases were the second
largest racial/ethnic group (15%) among the youngest age
group (45–54 years) but the smallest group (6%) among
the oldest age group (85? years). Hispanics and Asian/
Pacific Islanders represented 10–14% and 4–7% of the
cases, respectively, across the 10-year age groups. The
majority of cases was of a nonaggressive type, localized
disease, and moderately differentiated.
Higher incidence rates of prostate cancer were associ-
ated with increasing levels of SES across all racial/ethnic
groups (Table 2). Among all racial/ethnic groups com-
bined, those at the highest quintile of SES had a 28%
higher incidence rate of prostate cancer than those in the
lowest quintile (95% CI: 1.25–1.30). The largest difference
in SES-specific rates was observed among Hispanics, with
an incidence rate of prostate cancer that was 80% higher
among men in the highest quintile of SES in comparison to
those in the lowest SES quintile (95% CI: 1.68–1.92). In a
stratified analysis by severity of disease, a similar pattern
was observed for both nonaggressive and aggressive dis-
ease such that significantly higher rates of prostate cancer
were observed with increasing gradients of SES (Table 2).
In particular, for men with aggressive disease those at the
highest quintile of SES had a 1.2-fold significant increased
risk of prostate cancer than those at the lowest SES quin-
tile. This same pattern was seen for all four racial/ethnic
groups.
In contrast to the expected exponential increase in
prostate cancer incidence with age [24], for all SES levels a
peak in incidence rate was seen for African-Americans and
non-Hispanic Whites at 65–74 years of age, while for
Hispanics and Asians/Pacific Islanders incidence rates
peaked at 75–84 years (Table 3). Furthermore, different
racial/ethnic-specific patterns in incidence rates were seen
for younger and older age groups. Specifically, among
younger men aged 45–64 years, African-Americans had
the highest incidence rates followed by non-Hispanic
Whites, Hispanics, and Asians for each level of SES. Most
notably, African-Americans (45–64 years) had a significant
twofold higher incidence rate of prostate cancer in com-
parison to non-Hispanic Whites, irrespective of SES.
Among older men aged 75–84 years, Hispanics, following
African-Americans, had the second highest incidence rates
of prostate cancer across all SES quintiles, while non-
Hispanics Whites and Asians had the lowest incidence
Cancer Causes Control (2009) 20:1431–1440 1433
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rates. This pattern was similar among men aged C85 years
with the exception of those at the lowest SES level. For
aggressive prostate cancer, incidence rates were highest for
African-Americans in all age groups and were twofold to
threefold higher than the rates of non-Hispanic Whites
among men aged 45–64 years (see ‘‘Supplementary
Table 2’’). Among men aged 65–84 years, higher inci-
dence rates were also noted in Hispanic men, with rates
between those of African-Americans and non-Hispanics
and Whites, particularly among those at higher SES levels
(Q3, Q4, and Q5) (see ‘‘Supplementary Table 2’’).
Socioeconomic status and prostate cancer mortality
Table 4 shows distributions of the 8,997 prostate cancer
deaths by race/ethnicity and SES. Non-Hispanic Whites
comprised the majority (55 to 79%) of deaths in all age
groups. SES and prostate cancer mortality rates were
inversely associated with decreasing mortality rates seen
with increasing levels of SES (Table 5). Men at the highest
quintile of SES had a 12% significant reduction in risk of
prostate cancer death compared to men at the lowest SES
quintile (RR = 0.88; 95% CI: 0.82–0.94). Although within
each racial/ethnic group there were no significant differ-
ences in mortality rates across levels of SES, non-Hispanic
Whites demonstrated a trend of lower morality rates
associated with higher SES levels (Table 5).
Table 6 displays the racial/ethnic-specific patterns of
prostate cancer mortality rates across SES levels by 10-
year age groups. Across all age groups, African-Americans
had the highest mortality rates of prostate cancer for all
quintiles of SES, with mortality rates that were twofold to
fivefold higher than those of non-Hispanics Whites. Asian/
Pacific Islanders had the lowest rates of prostate cancer
mortality for all SES quintiles that were generally less than
half that of the rates of non-Hispanic Whites. In most age
and SES groups, Hispanics had slightly lower mortality
rates than non-Hispanic Whites.
Discussion
In this large multiethnic population, population-based ser-
ies of prostate cancer patients, increasing levels of SES
were associated with higher incidence and lower mortality
rates of prostate cancer. Furthermore, across all levels of
SES, African-Americans had a substantially larger burden
of prostate cancer deaths than other racial/ethnic groups,
suggesting that SES alone cannot entirely account for the
racial/ethnic differences in prostate cancer mortality.
Table 1 Characteristics of incident prostate cancer cases by 10-year age groups, California, 1998–2002 (n = 98,484)
Years 45–54 55–64 65–74 75–84 85?
Number 7,374 25,712 38,206 22,390 4,802
Race/ethnicity, n (%)
Non-Hispanic White 4,986 (67.6) 18,035 (70.1) 26,958 (70.6) 16,694 (74.6) 3,719 (77.4)
African-American 1,101 (14.9) 3,065 (11.9) 3,203 (8.4) 1,362 (6.1) 290 (6.0)
Hispanic 979 (13.3) 3,340 (13.0) 5,393 (14.1) 2,675 (11.9) 497 (10.3)
Asian/Pacific Islander 308 (4.2) 1,275 (5.0) 2,652 (6.9) 1,659 (7.4) 296 (6.2)
Severity, n (%)a
Non-aggressive 5,272 (74.8) 18,292 (74.6) 26,399 (73.8) 13,300 (69.6) 1,511 (53.8)
Aggressive 1,775 (25.2) 6,241 (25.4) 9,391 (26.2) 5,805 (30.4) 1,295 (46.1)
Stage, n (%)a
Localized 6,089 (84.3) 21,530 (85.7) 32,484 (88.0) 17,638 (87.0) 2,520 (74.9)
Regional/distant 1,136 (15.7) 3,593 (14.3) 4,442 (12.0) 2,625 (13.0) 846 (25.1)
Grade, n (%)a
Well differentiated; I 244 (3.4) 1,022 (4.1) 1,887 (5.1) 1,228 (6.1) 190 (6.2)
Moderately differentiated; II 5,758 (80.5) 19,673 (78.8) 27,205 (74.2) 13,548 (67.2) 1,595 (52.0)
Poorly/undifferentiated; III/IV 1,155 (16.1) 4,277 (17.1) 7,565 (20.6) 5,375 (26.7) 1,281 (41.2)
Socioeconomic status quintile, n (%)
Q1 771 (10.5) 2,916 (11.3) 4,855 (12.7) 2,926 (13.1) 690 (14.4)
Q2 1,121 (15.2) 4,040 (15.7) 6,482 (17.0) 4,025 (18.0) 944 (19.7)
Q3 1,527 (20.7) 5,085 (19.8) 7,962 (20.8) 4,674 (20.9) 1,008 (21.0)
Q4 1,780 (24.1) 5,650 (22.0) 8,496 (22.2) 4,991 (22.3) 1,074 (22.3)
Q5 2,175 (29.5) 8,021 (31.2) 10,411 (27.2) 5,774 (25.8) 1,086 (22.6)
a Numbers do not add up to 98,484 due to missing data
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The elevated incidence rate of prostate cancer associated
with higher levels of SES is likely attributable at least in
some part to variation in access and utilization of health
services; in particular, prostate cancer screening through
PSA testing. PSA testing greatly increases the detection of
prostate tumors, which leads at the population-level to
elevated incidence rates of prostate cancer. Studies have
reported that men at higher levels of SES are more likely to
undergo PSA testing [25, 26], ultimately influencing the
amount of disease in the population. The peak in incidence
rates of prostate cancer among non-Hispanics Whites and
African-Americans at 65–74 years of ages are in agree-
ment with previous SEER reports [2] and may reflect
heavier screening practices at earlier ages, while the later
peak among Hispanics and Asian/Pacific Islanders at 75–
84 years may reflect later adoption and lower utilization of
PSA screening. Prior research has shown that Asians and
Hispanics are less likely to receive physician discussions of
PSA testing than higher risk Whites and African-Ameri-
cans [27].
A consistent racial/ethnic-specific pattern of incidence
rates across SES levels was observed only among younger
adult men (\65 years). To our knowledge, our findings of
an increased incidence of prostate cancer among older
Hispanics (75–85 years) at the higher levels of SES rela-
tive to non-Hispanic Whites have not been reported pre-
viously. In a national study of cancer among US Hispanics,
Howe et al. [11] reported that Hispanics are less likely to
have health care coverage than non-Hispanics Whites,
especially among those younger than 65 years. With more
health care coverage for older Hispanics and better
resources for those at higher levels of SES, such men may
have improved access and utilization of screening services
that otherwise may have not been available—this may
account for the higher incidence rates among this particular
group of Hispanics. Our findings are in line with two
similar yet smaller studies in Los Angeles [5] and the San
Francisco Bay Area [10] in which across all levels of SES a
similar racial/ethnic-specific pattern in age-adjusted inci-
dence rates were seen with the exception of greater
Table 2 Prostate cancer (PCa) incidence rates (per 100,000) among men 45 years and older by SES and race/ethnicity, California 1998–2002
SES Total PCa Localized PCa Aggressive PCa
n Rate RR (95% CI) n Rate RR (95% CI) n Rate RR (95% CI)
All Q1 12,158 411.7 1.00 7,383 84.4 1.00 3,177 37.3 1.00
Q2 16,612 401.1 0.97 (0.95–1.00) 10,501 86.7 1.03 (1.00–1.06) 4,371 36.7 0.98 (0.94–1.04)
Q3 20,256 434.0 1.05 (1.03–1.08) 13,359 98.1 1.16 (1.13–1.20) 4,991 37.3 1.00 (0.96–1.05)
Q4 21,991 455.6 1.11 (1.08–1.13) 14,783 104.9 1.24 (1.21–1.28) 5,451 39.4 1.06 (1.01–1.11)
Q5 27,467 525.5 1.28 (1.25–1.30) 19,044 124.3 1.47 (1.43–1.51) 6,633 44.7 1.20 (1.15–1.25)
Non-Hispanic White Q1 4,788 441.6 1.00 2,960 94.8 1.00 1,199 38.6 1.00
Q2 10,251 399.8 0.91 (0.87–0.94) 6,546 88.6 0.93 (0.89–0.98) 2,640 36.0 0.93 (0.87–1.00)
Q3 14,744 435.5 0.99 (0.95–1.02) 9,833 100.6 1.06 (1.02–1.11) 3,491 36.0 0.93 (0.87–1.00)
Q4 17,115 460.4 1.04 (1.01–1.08) 11,630 108.0 1.14 (1.10–1.19) 4,112 38.6 1.00 (0.94–1.07)
Q5 23,494 545.4 1.24 (1.20–1.27) 16,397 130.5 1.38 (1.32–1.43) 5,538 45.2 1.17 (1.10–1.25)
African-American Q1 2,710 711.3 1.00 1,599 142.0 1.00 697 63.5 1.00
Q2 2,165 702.7 0.99 (0.93–1.05) 1,350 146.3 1.03 (0.96–1.11) 583 65.6 1.03 (0.92–1.16)
Q3 1,776 738.7 1.04 (0.97–1.11) 1,180 162.9 1.15 (1.06–1.24) 439 62.8 0.99 (0.87–1.13)
Q4 1,500 798.1 1.12 (1.05–1.20) 1,006 176.7 1.24 (1.14–1.36) 386 70.5 1.11 (0.97–1.28)
Q5 867 933.7 1.31 (1.22–1.43) 614 219.5 1.55 (1.40–1.71) 220 85.1 1.34 (1.13–1.60)
Hispanic Q1 3,946 348.7 1.00 2,407 70.4 1.00 30 32.0 1.00
Q2 3,147 393.1 1.13 (1.07–1.19) 1,950 80.6 1.15 (1.07–1.22) 34.1 36.6 1.14 (1.04–1.26)
Q3 2,511 440.7 1.26 (1.20–1.33) 1,595 93.7 1.33 (1.24–1.43) 37.4 40.5 1.27 (1.14–1.41)
Q4 1,837 471.0 1.35 (1.27–1.43) 1,179 99.8 1.42 (1.32–1.53) 41.1 45.2 1.41 (1.26–1.59)
Q5 1,443 625.9 1.80 (1.68–1.92) 967 139.1 1.98 (1.82–2.14) 53.2 59.3 1.85 (1.63–2.11)
Asian/Pacific Islander Q1 714 234.3 1.00 417 47.1 1.00 208 24.0 1.00
Q2 1,049 242.6 1.04 (0.94–1.14) 655 51.9 1.10 (0.97–1.25) 282 22.5 0.94 (0.78–1.14)
Q3 1,225 278.1 1.19 (1.08–1.31) 751 57.8 1.23 (1.09–1.39) 385 30.4 1.27 (1.07–1.52)
Q4 1,539 306.5 1.31 (1.19–1.43) 968 64.1 1.36 (1.21–1.53) 443 31.4 1.31 (1.11–1.56)
Q5 1,663 297.4 1.27 (1.16–1.39) 1,066 62.9 1.33 (1.19–1.50) 487 31.4 1.31 (1.11–1.56)
Age-adjusted to the 2000 US standard population
Cancer Causes Control (2009) 20:1431–1440 1435
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incidence of prostate cancer among Hispanics than that of
Whites for those at the higher levels of SES. Age-stratified
effects as shown in our study were not examined in these
previous reports [5, 10].
Because screening practices greatly influence the inci-
dence rates of prostate cancer, we also examined mortality
as it may serve as a better index of risk across groups and
may reflect the most clinically relevant forms of disease.
The lower mortality rates of prostate cancer seen with
higher levels of SES are likely attributed to factors linked
to a better health status by affording optimal use of medical
services such as early detection and treatment regimens,
acquiring pertinent health information and education, and
avoiding high risk health behaviors [15]. This overall
inverse association between mortality and SES was largely
driven by non-Hispanics Whites with the remaining racial/
ethnic groups demonstrating no association. This could be
explained due to insufficient power among the remaining
racial/ethnic groups given their smaller numbers of deaths
and fewer overall Census numbers at higher levels of SES.
In addition, this could be due to inadequacy of our SES
index in capturing SES parameters that are most relevant
for certain non-White racial/ethnic groups (discussed
below). Lastly, these findings may suggest that SES does
not play a role in prostate cancer mortality among African-
Americans, Hispanics, and Asian/Pacific Islanders.
For every level of SES, African-Americans had the
highest burden of prostate cancer deaths in comparison to
other three racial/ethnic groups. These findings are in
agreement with three previous studies that reported that the
measures of SES cannot account for the differences in
mortality/survival between African-Americans and Whites
Table 4 Characteristics of prostate cancer deaths by 10-year age groups, California, 1999–2001 (n = 8,997)
Years 45–54 55–64 65–74 75–84 85?
Number 125 596 1910 3787 2579
Race/ethnicity, n (%)
Non-Hispanic White 69 (55.2) 397 (66.6) 1,291 (67.6) 2,887 (76.2) 2044 (79.3)
African-American 29 (23.2) 112 (18.8) 289 (15.1) 367 (9.7) 185 (7.2)
Hispanic 25 (20.0) 74 (12.4) 276 (14.5) 367 (9.7) 211 (8.2)
Asian/Pacific Islander 2 (1.6) 13 (2.2) 54 (2.8) 166 (4.4) 139 (5.4)
Socioeconomic status quintile, n (%)
Q1 24 (19.2) 94 (15.8) 315 (16.5) 527 (13.9) 345 (13.4)
Q2 27 (21.6) 147 (24.7) 408 (21.4) 735 (19.4) 527 (20.4)
Q3 26 (20.8) 131 (22.0) 414 (21.7) 870 (23.0) 560 (21.7)
Q4 25 (20.0) 126 (21.1) 382 (20.0) 870 (23.0) 572 (22.2)
Q5 23 (18.4) 98 (16.4) 391 (20.5) 785 (20.7) 575 (22.3)
Table 5 Prostate cancer mortality rates (per 100,000) among men 45 years and older by SES and race/ethnicity, California 1999–2001
SES All Non-Hispanic White African-American Hispanic Asian/Pacific Islander
n Rate RR (95% CI) n Rate RR (95% CI) n Rate RR (95% CI) n Rate RR (95% CI) n Rate RR (95% CI)
Q1 1,305 33.5 1.00 559 33.1 1.00 355 67.6 1.00 338 27.3 1.00 53 13.9 1.00
Q2 1,844 32.5 0.97
(0.90–1.04)
1,254 32.6 0.99
(0.89–1.09)
254 64.8 0.96
(0.81–1.13)
243 27.1 0.99
(0.83–1.18)
93 19.3 1.38
(0.97–1.99)
Q3 2,001 31.0 0.93
(0.86–0.99)a
1,576 31.4 0.95
(0.86–1.05)
176 64.7 0.96
(0.79–1.15)
177 27.9 1.02
(0.84–1.24)
72 15.1 1.09
(0.74–1.59)
Q4 1,975 29.6 0.88
(0.82–0.95)a
1,635 29.9 0.91
(0.82–1.00)
134 72.5 1.07
(0.87–1.32)
123 27.9 1.02
(0.82–1.27)
83 15.9 1.14
(0.79–1.65)
Q5 1,872 29.5 0.88
(0.82–0.94)a
1,664 30.7 0.93
(0.84–1.02)
63 73.5 1.09
(0.81–1.44)
72 27.8 1.02
(0.77–1.33)
73 14.0 1.01
(0.69–1.47)
Age-adjusted to the 2000 US standard population
a The overall lower mortality rate in comparison with racial/ethnic specific rates is attributed to non-Hispanic Whites and Asian/Pacific Islanders
having larger population denominators at the higher SES levels in comparison with lower SES levels with Blacks and Hispanics having larger
population denominators at lower SES levels in comparison
Cancer Causes Control (2009) 20:1431–1440 1437
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[15, 17, 20]. Similarly, in a multiethnic cohort study of
African-Americans, Whites, and Asian-Americans, the
disparity in prostate cancer survival and stage of presen-
tation could not be eliminated by adjustment of SES and
comorbidities [16]. We conducted a comparable survival
analysis of men in our study diagnosed with prostate cancer
from 1998 to 2002, adjusting for SES, stage, and grade;
hazard ratios (HR) for prostate cancer death confirmed
such disparity in risk: African-Americans (HR = 1.20;
95% CI: 1.08–1.33), Asian/Pacific Islanders (HR = 0.59;
95% CI: 0.51–0.68), and Hispanics (HR = 0.89; 95% CI:
0.81–0.98) when compared to non-Hispanic Whites.
Our findings suggest substantial influences of both
innate and lifestyle factors in the differences in prostate
cancer rates across groups. The consistent racial/ethnic
disparity in incidence rates for all levels of SES among
younger men (ages \55 years) indirectly support an
important biological component to disease risk as early
ages at diagnoses have been linked to biological con-
tributors to disease. Exciting developments from recent
genetic association studies, an admixture study of prostate
cancer among African-Americans [28] and a multiethnic
fine-mapping study [29], revealed a particular region on
chromosome 8q24 that may contribute to the higher
incidence of prostate cancer among African-Americans in
comparison with non-Hispanic Whites. Compelling evi-
dence provides strong support that genetic factors may
account for at least part of racial/ethnic differences in
disease. Lifestyle and contextual factors have yet to
convincingly identify specific contributors; some studies
have implicated dietary fat [30, 31], but the results are
conflicting [32]. Regardless, our data suggest that the
ongoing search for environmental causes of prostate
cancer continues to be warranted.
Differences in treatment practices are an important
consideration in evaluating racial/ethnic differences in
prostate cancer mortality. Cancer registry data do not
include detailed information regarding treatment, so we
were unable to account for potential differences in treat-
ment practices across racial/ethnic groups. Previous studies
have reported that African-Americans are more likely to
undergo less aggressive treatment than Whites [14, 33, 34],
which may account for some of the observed differences in
mortality. Recently, in a large California cancer registry
study of differences in prostate cancer survival between
African-Americans and Whites (n = 109,270), adjustment
for stage and treatment eliminated most of the racial dif-
ference in survival; and with additional adjustment for
SES, grade, and year of diagnosis, the survival difference
between African-Americans and Whites was eliminated
(HR = 1.00; 95% CI: 0.93–1.08) [13]. Although these
findings indicate treatment differences are largely
accountable for differences in survival, biological and
environmental factors remain important contributors to
racial/ethnic differences in the development of prostate
cancer.
Our study has several limitations that warrant discus-
sion. The use of a neighborhood-level index of SES is
subjected to ecological fallacy such that incorrect infer-
ences of individual levels of SES may have been made. In
addition, by using overall census data to construct our
index of SES, we may have overlooked factors that are
particularly relevant for specific racial/ethnic groups. For
example, Krieger et al. [35] report that for homes of equal
value, African-Americans pay higher taxes in comparison
with Whites, and for a given level of education, the eco-
nomic returns are higher for Whites in comparison with
African-Americans and Hispanics. This suggests that cer-
tain racial/ethnic groups at the same level of SES may not
share the same level of power, prestige, and opportuni-
ties—variables that can capture these factors may improve
SES measurement [22]. While we acknowledge SES may
be measured with some error in our study, we have evi-
dence that our index of SES is of sufficient quality to
uncover important SES and cancer associations as seen in
the literature (SES and breast cancer [22] and Hodgkin-
lymphoma [36]), providing certain confidence that our SES
index is valid.
There are several strengths to this study. Foremost, this
is the largest and most diverse study of prostate cancer
disparities to date, having 98,000 incident prostate cancer
cases and 9,000 prostate cancer deaths with substantial
numbers of cases from four major racial/ethnic groups. In
addition, as a population-based study our findings may be
generalized to the diverse population of California at large.
While our use of census data to derive an area measure of
SES may not completely reflect data at the individual level,
area-based measures have been suggested to capture ele-
ments of the socioeconomic environment that may not be
obtainable by individual-level data [37].
In summary, the present study suggests that socioeco-
nomic status alone does not appear to account for the dif-
ferences in prostate cancer burden among African-
Americans, non-Hispanic Whites, Hispanics, and Asian/
Pacific Islanders. Large multiethnic studies with comple-
mentary individual- and area-level measures of SES are
needed to corroborate our findings. The challenge remains
to disentangle the complexities of racial/ethnic differences
in screening, treatment, biological and environmental fac-
tors that contribute to differences in risk across groups.
Such information will greatly aid the development of more
targeted interventions to improve the social inequalities in
prostate cancer incidence and mortality.
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